Literature DB >> 19005640

Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity.

J Ludvigsson.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 19005640     DOI： 10.1007/s00125-008-1211-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  9 in total

Review 1.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997.

Authors: 
Journal:  Allergy       Date:  1998       Impact factor: 13.146

2.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

3.  Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.

Authors:  I Raz; D Elias; A Avron; M Tamir; M Metzger; I R Cohen
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

4.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

5.  Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.

Authors:  Nanette C Schloot; Guido Meierhoff; Csaba Lengyel; Gyözö Vándorfi; József Takács; Pál Pánczél; László Barkai; László Madácsy; Tamás Oroszlán; Peter Kovács; Gábor Sütö; Tadej Battelino; Nora Hosszufalusi; György Jermendy
Journal:  Diabetes Metab Res Rev       Date:  2007-05       Impact factor: 4.876

6.  Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

Authors:  Jay S Skyler; Jeffrey P Krischer; Joseph Wolfsdorf; Catherine Cowie; Jerry P Palmer; Carla Greenbaum; David Cuthbertson; Lisa E Rafkin-Mervis; H Peter Chase; Ellen Leschek
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

7.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

Authors:  Kirsti Näntö-Salonen; Antti Kupila; Satu Simell; Heli Siljander; Tiina Salonsaari; Anne Hekkala; Sari Korhonen; Risto Erkkola; Jukka I Sipilä; Lotta Haavisto; Marja Siltala; Juhani Tuominen; Jari Hakalax; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Tuula Simell; Mikael Knip; Olli Simell
Journal:  Lancet       Date:  2008-09-22       Impact factor: 79.321

8.  GAD treatment and insulin secretion in recent-onset type 1 diabetes.

Authors:  Johnny Ludvigsson; Maria Faresjö; Maria Hjorth; Stina Axelsson; Mikael Chéramy; Mikael Pihl; Outi Vaarala; Gun Forsander; Sten Ivarsson; Calle Johansson; Agne Lindh; Nils-Osten Nilsson; Jan Aman; Eva Ortqvist; Peter Zerhouni; Rosaura Casas
Journal:  N Engl J Med       Date:  2008-10-08       Impact factor: 91.245

9.  A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Authors:  Kevan C Herold; Stephen E Gitelman; Umesh Masharani; William Hagopian; Brygida Bisikirska; David Donaldson; Kristina Rother; Beverly Diamond; David M Harlan; Jeffrey A Bluestone
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461
  9 in total
  7 in total

1.  Immune intervention in children with type 1 diabetes.

Authors:  Johnny Ludvigsson
Journal:  Curr Diab Rep       Date:  2010-10       Impact factor: 4.810

Review 2.  The role of immunomodulation therapy in autoimmune diabetes.

Authors:  Johnny Ludvigsson
Journal:  J Diabetes Sci Technol       Date:  2009-03-01

3.  Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.

Authors:  J Ludvigsson; M Hjorth; M Chéramy; S Axelsson; M Pihl; G Forsander; N-Ö Nilsson; B-O Samuelsson; T Wood; J Aman; E Ortqvist; R Casas
Journal:  Diabetologia       Date:  2010-11-30       Impact factor: 10.122

4.  GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.

Authors:  Camilla Skoglund; Mikael Chéramy; Rosaura Casas; Johnny Ludvigsson; Christiane S Hampe
Journal:  Pediatr Diabetes       Date:  2011-08-16       Impact factor: 4.866

5.  Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.

Authors:  Stina Axelsson; Mikael Chéramy; Maria Hjorth; Mikael Pihl; Linda Akerman; Emanuela Martinuzzi; Roberto Mallone; Johnny Ludvigsson; Rosaura Casas
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

Review 6.  Therapies to Preserve β-Cell Function in Type 1 Diabetes.

Authors:  Johnny Ludvigsson
Journal:  Drugs       Date:  2016-02       Impact factor: 11.431

Review 7.  Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route.

Authors:  Johnny Ludvigsson
Journal:  Int J Mol Sci       Date:  2020-02-26       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.